Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 2/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ACLY | P53396 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6819822 | 0.85 | DAO (0.57) | DAOGSK3BKMT2AACLY | |
| SCHEMBL16237290 | 0.79 | GSK3B (0.36) | GSK3B | |
| SCHEMBL19505825 | 0.79 | LMNA (0.44) | KMT2AKDM4EMAPT | |
| SCHEMBL742144 | 0.73 | PTGES2 (0.42) | DAOGSK3BACLY | |
| SCHEMBL377802 | 0.73 | DAO (0.68) | DAOGSK3BKMT2AKDM4EMAPT | |
| SCHEMBL2265194 | 0.71 | PKM (0.35) | — | |
| SCHEMBL21453442 | 0.71 | CA1 (0.33) | HPGD | |
| SCHEMBL388122 | 0.69 | FBP1 (0.42) | — | |
| SCHEMBL456375 | 0.69 | DAO (0.42) | DAOGSK3BKDM4EMAPTHPGD | |
| SCHEMBL9997249 | 0.69 | DAO (0.44) | DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10160743-B2 | Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | JANSSEN SCIENCES IRELAND UC (IE) | 2018-12-25 | — | — | US | disclosed |
| EP-2997019-B1 | SULPHAMOYLTHIOPHENAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2018-08-08 | — | — | EP | disclosed |
| US-20160115149-A1 | SULPHAMOYLTHIOPHENAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2016-04-28 | — | — | US | disclosed |
| EP-2997019-A1 | SULPHAMOYLTHIOPHENAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | Janssen Sciences Ireland UC (IE) | 2016-03-23 | — | — | EP | disclosed |
| WO-2014184365-A1 | SULPHAMOYLTHIOPHENAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN R&D IRELAND (IE) | 2014-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10160743-B2 | Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | HBS1L, SLC10A1, NR1H4 | DAO 3447/4885GSK3B 1377/4885KMT2A 791/4885 |
| US-20160115149-A1 | SULPHAMOYLTHIOPHENAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | HBS1L, SLC10A1, NR1H4 | DAO 3447/4885GSK3B 1377/4885KMT2A 791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.